Microscopic polyangiitis: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Template)
Line 18: Line 18:
==Overview==
==Overview==
'''Microscopic polyangiitis (MPA) ''' is an ill-defined [[autoimmune disease]] characterized by pauci-immune, necrotizing, small-vessel [[vasculitis]] without clinical or pathological evidence of necrotizing granulomatous [[inflammation]]. Because many different organ systems may be involved, a wide range of symptoms are possible in MPA.
'''Microscopic polyangiitis (MPA) ''' is an ill-defined [[autoimmune disease]] characterized by pauci-immune, necrotizing, small-vessel [[vasculitis]] without clinical or pathological evidence of necrotizing granulomatous [[inflammation]]. Because many different organ systems may be involved, a wide range of symptoms are possible in MPA.
==Historical Perspective==
*[Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
*In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
*In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
==Classification==
*[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
:*[group1]
:*[group2]
:*[group3]
*Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].
==Pathophysiology==
*The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
*On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
*On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
==Cause==
==Cause==
This condition, the clinical picture of which may include many features of systemic lupus erythematosis, has been reported to have been caused by [[antibiotics]] and also by certain [[infection]]s, though, as with many autoimmune diseases, the causes remain to a large extent unknown.
This condition, the clinical picture of which may include many features of systemic lupus erythematosis, has been reported to have been caused by [[antibiotics]] and also by certain [[infection]]s, though, as with many autoimmune diseases, the causes remain to a large extent unknown.
==Differentiating [disease name] from other Diseases==
*[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
:*[Differential dx1]
:*[Differential dx2]
:*[Differential dx3]
==Epidemiology and Demographics==
* The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
* In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
===Age===
*Patients of all age groups may develop [disease name].
*[Disease name] is more commonly observed among patients aged [age range] years old.
*[Disease name] is more commonly observed among [elderly patients/young patients/children].
===Gender===
*[Disease name] affects men and women equally.
*[Gender 1] are more commonly affected with [disease name] than [gender 2].
* The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
===Race===
*There is no racial predilection for [disease name].
*[Disease name] usually affects individuals of the [race 1] race.
*[Race 2] individuals are less likely to develop [disease name].
==Risk Factors==
*Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
== Natural History, Complications and Prognosis==
*The majority of patients with [disease name] remain asymptomatic for [duration/years].
*Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
*If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
*Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
*Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].
==Diagnosis==
==Diagnosis==
===Diagnostic criteria===
===History and Symptoms===
===Physical examination===
===Laboratory findings===
Laboratory tests show an increased sedimentation rate, reduced red blood count, antineutrophil cytoplasmic antibodies (p-ANCA) directed against [MPO(a constituent of [[neutrophil]] granules), and [[protein]] and red blood cells in the [[urine]].   
Laboratory tests show an increased sedimentation rate, reduced red blood count, antineutrophil cytoplasmic antibodies (p-ANCA) directed against [MPO(a constituent of [[neutrophil]] granules), and [[protein]] and red blood cells in the [[urine]].   


The test for [[anti-glomerular basement membrane antibody]] (GBM), which is positive in [[Goodpasture's syndrome]], is negative.
The test for [[anti-glomerular basement membrane antibody]] (GBM), which is positive in [[Goodpasture's syndrome]], is negative.
===Imaging Findings===
*There are no [imaging study] findings associated with [disease name].
*[Imaging study 1] is the imaging modality of choice for [disease name].
*On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
*[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
=== Other Diagnostic Studies ===
*[Disease name] may also be diagnosed using [diagnostic study name].
*Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
==Treatment==
==Treatment==
===Medical Therapy===
The customary treatment involves long term dosage of [[prednisone]], alternated or combined with [[cytotoxic]] drugs, such as [[cyclophosphamide]] or [[azathioprine]]. [[Plasmapheresis]] may also be indicated in the acute setting to remove ANCA antibodies.
The customary treatment involves long term dosage of [[prednisone]], alternated or combined with [[cytotoxic]] drugs, such as [[cyclophosphamide]] or [[azathioprine]]. [[Plasmapheresis]] may also be indicated in the acute setting to remove ANCA antibodies.
===Surgery===
===Prevention===
==References==
==References==
{{reflist|2}}
{{reflist|2}}
==Related Chapters==
==Related Chapters==
* [[ANCA-associated vasculitides]]
* [[ANCA-associated vasculitides]]

Revision as of 13:23, 17 June 2016

Microscopic polyangiitis
ICD-10 M31.7
DiseasesDB 8193

WikiDoc Resources for Microscopic polyangiitis

Articles

Most recent articles on Microscopic polyangiitis

Most cited articles on Microscopic polyangiitis

Review articles on Microscopic polyangiitis

Articles on Microscopic polyangiitis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Microscopic polyangiitis

Images of Microscopic polyangiitis

Photos of Microscopic polyangiitis

Podcasts & MP3s on Microscopic polyangiitis

Videos on Microscopic polyangiitis

Evidence Based Medicine

Cochrane Collaboration on Microscopic polyangiitis

Bandolier on Microscopic polyangiitis

TRIP on Microscopic polyangiitis

Clinical Trials

Ongoing Trials on Microscopic polyangiitis at Clinical Trials.gov

Trial results on Microscopic polyangiitis

Clinical Trials on Microscopic polyangiitis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Microscopic polyangiitis

NICE Guidance on Microscopic polyangiitis

NHS PRODIGY Guidance

FDA on Microscopic polyangiitis

CDC on Microscopic polyangiitis

Books

Books on Microscopic polyangiitis

News

Microscopic polyangiitis in the news

Be alerted to news on Microscopic polyangiitis

News trends on Microscopic polyangiitis

Commentary

Blogs on Microscopic polyangiitis

Definitions

Definitions of Microscopic polyangiitis

Patient Resources / Community

Patient resources on Microscopic polyangiitis

Discussion groups on Microscopic polyangiitis

Patient Handouts on Microscopic polyangiitis

Directions to Hospitals Treating Microscopic polyangiitis

Risk calculators and risk factors for Microscopic polyangiitis

Healthcare Provider Resources

Symptoms of Microscopic polyangiitis

Causes & Risk Factors for Microscopic polyangiitis

Diagnostic studies for Microscopic polyangiitis

Treatment of Microscopic polyangiitis

Continuing Medical Education (CME)

CME Programs on Microscopic polyangiitis

International

Microscopic polyangiitis en Espanol

Microscopic polyangiitis en Francais

Business

Microscopic polyangiitis in the Marketplace

Patents on Microscopic polyangiitis

Experimental / Informatics

List of terms related to Microscopic polyangiitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Synonyms and keywords: MPA

Overview

Microscopic polyangiitis (MPA) is an ill-defined autoimmune disease characterized by pauci-immune, necrotizing, small-vessel vasculitis without clinical or pathological evidence of necrotizing granulomatous inflammation. Because many different organ systems may be involved, a wide range of symptoms are possible in MPA.

Historical Perspective

  • [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
  • The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Cause

This condition, the clinical picture of which may include many features of systemic lupus erythematosis, has been reported to have been caused by antibiotics and also by certain infections, though, as with many autoimmune diseases, the causes remain to a large extent unknown.

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

  • The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Patients of all age groups may develop [disease name].
  • [Disease name] is more commonly observed among patients aged [age range] years old.
  • [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected with [disease name] than [gender 2].
  • The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

  • There is no racial predilection for [disease name].
  • [Disease name] usually affects individuals of the [race 1] race.
  • [Race 2] individuals are less likely to develop [disease name].

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic criteria

History and Symptoms

Physical examination

Laboratory findings

Laboratory tests show an increased sedimentation rate, reduced red blood count, antineutrophil cytoplasmic antibodies (p-ANCA) directed against [MPO(a constituent of neutrophil granules), and protein and red blood cells in the urine.

The test for anti-glomerular basement membrane antibody (GBM), which is positive in Goodpasture's syndrome, is negative.

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease name].
  • On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

The customary treatment involves long term dosage of prednisone, alternated or combined with cytotoxic drugs, such as cyclophosphamide or azathioprine. Plasmapheresis may also be indicated in the acute setting to remove ANCA antibodies.

Surgery

Prevention

References

Related Chapters

Template:Diseases of the musculoskeletal system and connective tissue de:Mikroskopische Polyangiitis nl:Microscopische polyangiitis


Template:WikiDoc Sources